Description
(S,S)-ICG-001 is an inhibitor of Wnt/β-catenin signaling. Treatment of nasopharyngeal carcinoma cells with ICG-001 led to reduced capability of the cells to adhere to extracellular matrix and capillary endothelial cells, and reduced tumor cell migration and invasion. In high-fat diet mice, treatment improved renal function, inhibited proinflammatory cytokines expression, reduced proteinuria and alleviated podocyte injury. Treatment of cancer stem-like cells with both ICG-001 and metformin together led to decreased expression of CSC markers and promoted autophagy and apoptosis synergistically.